The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price has been amongst the best performers on the Australian share market this morning.
In early trade the biopharmaceutical company’s shares are 3.5% higher to $1.50.
Why is the Paradigm share price storming higher?
Investors have been fighting to get hold of the company’s shares this morning after it provided an update on its pilot phase 2a randomised, double-blinded placebo-controlled clinical trial in participants with chronic Ross River virus.
Ross River virus is a mosquito transmitted alphavirus that causes epidemic polyarthritis and arthralgias, with about half of patients also experiencing fever and rash. It is Australia’s most common arbovirus with about 5,000 cases notified.
According to the release, the company met its primary end point of safety in the clinical trial which saw participants with chronic Ross River virus induced arthralgia (joint pain or joint stiffness) treated with injectable pentosan polysulfate sodium (iPPS).
In addition to this, the clinical trial’s secondary endpoint was to obtain signals of efficacy of iPPS with regard to alleviation of disease symptoms. This was achieved, with the trial demonstrating a reduction in disease symptoms.
Paradigm’s chief executive officer, Paul Rennie, was very pleased with the trial results and the implications for iPPS.
He said: “We are very pleased to see that this small pilot RRV study has yielded very promising safety data and key efficacy outcomes in the reduction of disease symptoms in this debilitating chronic phase of the disease. The human data on the effects of iPPS in RRV induced arthralgia together with our preclinical work on CHIK-V will progress our commercial discussions with US Department of Defense.”
And here is another hot small cap stock that could be next in line for strong gains.
A little-known ASX company just unlocked what some experts think could be the key to profiting off the coming marijuana boom.
And make no mistake – it is coming. To the tune of an estimated $US22 billion.
Cannabis legalisation is sweeping over North America, and full legalisation arrived in Canada in October 2018.
Here's the best part: we think there's one ASX stock that's uniquely positioned to profit immensely from this explosive new industry... taking savvy investors along for what could be one heck of a ride.
AND, this is the first time The Motley Fool Australia has EVER put a BUY recommendation on a marijuana stock.
Simply click below to learn more on how you can profit from the coming cannabis boom.
James Mickleboro owns shares in Telix. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.